Investment
Still got some money to invest safely? GICs look interesting again


|
Stay alert if you’re an investor who favours the safety of GICs.
Financial markets are revising the outlook for inflation, and in turn, interest rates. Keep your eye on Government of Canada bond yields to follow the action for rates on guaranteed investment certificates.
The yield on the five-year Canada bond, an influence on five-year GICs, jumped this week to 3.4 per cent early Friday from 3 per cent a week earlier. This sizable move by bond market standards was brought to you by the April inflation report from Statistics Canada. It showed that the year-over-year inflation rate last month edged up to 4.4 per cent from 4.3 per cent in March.
Discouraging is the word to describe this change, given that inflation has been falling hard since reaching 8.1 per cent in June 2022. Financial markets had expected inflation to be around 3 per cent late this year and rate cuts to start happening around that time or in early 2024. Now, bets for a rate increase this summer are piling up.
Bonds have fallen in price in reaction to this changed outlook, which is why yields are up for government and corporate bonds. Expect GICs to follow if bond yields hold at recent levels.
The highest GIC rates currently are for one-year terms – expect 4.75 per cent to 5 per cent from alternative banks and trust companies and 5 per cent or slightly more from deposit brokers.
Five-year GIC rates are generally in the 4.4 to 4.75 per cent range. We could see these rates move higher if five-year bond yields hold and the spring housing market stays hot. GIC issuers sometimes juice their rates a bit to attract money for mortgage lending.
Short-term GIC rates are usually significantly lower than long-term rates. We’re seeing the opposite now because markets see potential for interest rates to rise in the near term and then fall back in the medium term as the economy slows and possibly lapses into recession.
Inflation will eventually fall to the preferred range around 2 to 3 per cent. When it does, GICs that lock in rates in the 4 per cent range and higher will look darn fine in your portfolio.
— Rob Carrick, personal finance columnist
This is the Globe Investor newsletter, published three times each week. If someone has forwarded this e-mail newsletter to you or you’re reading this on the web, you can sign up for the newsletter and others on our newsletter signup page.
Stocks to ponder
Brookfield Property Partners (BPYP-PR-A-T) Real estate companies with exposure to office buildings are struggling amid high vacancy rates and an uncertain future as many people continue to work from home. If buying the beaten-up units of real estate investment trusts at the depths of despair sounds too risky, here’s another approach: Take a look at the preferred shares of Brookfield Property Partners, which can yield more than 10 per cent right now. There’s certainly risk here, but a compelling opportunity too, says David Berman.
The Rundown
Don’t be fooled by gold’s glitter
Time to buy gold? As the legendary metal nears all-time highs – and headlines project more of the same ahead – it may seem intriguing. But beware: Gold is more volatile than stocks, with lower long-term returns than bonds. It requires impeccable market timing – otherwise, it is a drag. If you can’t time stocks, which rise far more often than fall, don’t try gold, argues billionaire investor Ken Fisher.
U.S. debt ceiling deal could stall safety flight fueling megacap rally
A potential deal to lift the U.S. debt ceiling could spur money managers to pare holdings in the massive technology and growth stocks that have been havens this year and shift into the rest of the market, reports Reuters’ David Randall.
How to beat the pros, Part 5: Two stocks you never heard of that fit our investing strategy
Portfolio managers Jason Del Vicario and Steven Chen are back with the next instalment of their beat the pros series. This time, they look at two little-known stocks that they think are going to do very well in the years ahead.
Why is the U.S. dollar so strong again?
If investors agree on one thing this year, it’s that the dollar is going to fall. That’s made the greenback’s 2% bounce over the last month particularly confusing. Harry Robertson of Reuters explains what’s behind the dollar’s recent rally.
Investors favour Japan’s rising sun over China’s fading star
Long Japan, short China. If there is a general macro, relative value trade playing out right now, it might be that as the contrasting fortunes of Asia’s economic and financial behemoths become starker by the day, as Reuters’ Jamie McGeever reports.
Others (for subscribers)
Number Cruncher: 10 U.S. stocks with attractive fundamentals in hot sectors
Number Cruncher: 10 mining stocks facing climate-change risk
Number Cruncher: 20 undervalued large cap stocks on the TSX
Friday’s analyst upgrades and downgrades
Thursday’s analyst upgrades and downgrades
Thursday’s Insider Report: Million-dollar purchases in these two dividend stocks
Globe Advisor
Why this $1.75-billion money manager has more than half of his portfolio in cash
Why early RRIF withdrawals don’t work for most retirees
Record buyback spree attracts shareholder complaints
Are you a financial advisor? Register for Globe Advisor (www.globeadvisor.com) for free daily and weekly newsletters, in-depth industry coverage and analysis.
Ask Globe Investor
Question: What is the best way to reinvest dividends?
Answer: Reinvesting dividends is one of the most effective ways to build wealth over the long run. That’s because it harnesses the power of compound growth, which is an investor’s greatest ally.
In the old days, reinvesting dividends was a cumbersome process. You had to enroll your shares in the company’s dividend reinvestment plan (DRIP), which required obtaining the shares certificates from your broker – for which there was a fee – and registering them in your name with the company’s transfer agent. When it came time to sell, you had to deliver your shares to a broker to carry out the transaction.
It was a pain in the behind, but the benefit of these traditional company-operated DRIPs was – and still is – that they support fractional share purchases. That means every penny of your dividend gets reinvested. Even as electronic record-keeping has replaced paper share certificates at many companies, these DRIPs still operate in much the same way.
Nowadays, investors have many more options for reinvesting dividends.
Most discount brokers now offer their own in-house DRIPs. The advantage of these plans is that you don’t have to register the shares in your own name – they stay with the broker – and you have more control over the timing and price when you sell. The downside is that most broker-operated plans only allow you to purchase whole shares. So, for example, if you receive $50 worth of dividends and the shares you’re reinvesting in trade at $40, you’ll acquire one additional share and the remaining $10 will sit in cash. That means you won’t get the full benefit of compounding.
The good news is that there are some easy workarounds.
One solution is to sweep the residual cash into a low-cost index mutual fund periodically. Mutual funds don’t charge commissions on purchases, so it’s a cost-effective method. What’s more, mutual funds allow partial unit purchases and reinvest their dividends by default, so they make the most of compounding. The disadvantage of this method is that mutual funds typically charge relatively high management expense ratios (MERs).
But there’s a way around that, too. A few years ago, with the arrival of commission-free exchange-traded funds at many brokers, I stopped using mutual funds to soak up cash and turned to ultra low-cost ETFs instead. For example, one of the ETFs I use is the BMO S&P/TSX Capped Composite Index ETF (ZCN), which has an MER of just 0.06 per cent. There are many other low-cost ETFs out there; I suggest you check to see if your broker supports commission-free ETF trades and, if so, which ones qualify.
I still occasionally buy shares of individual companies – and pay a commission – if I have a chunk of cash sitting around and a stock looks especially attractive. But the simplicity and cost-effectiveness of sweeping cash into a low-cost ETF is appealing. It makes the most of compounding, with the added benefit of diversification.
–John Heinzl (E-mail your questions to jheinzl@globeandmail.com)
What’s up in the days ahead
Take a bow readers – so far, you’re faring much better than us Globe staff in our recently launched investing club. Ian McGugan will provide an update.
More drama on the horizon: World market themes for the week ahead
Click here to see the Globe Investor earnings and economic news calendar.
More Globe Investor coverage
For more Globe Investor stories, follow us on Twitter @globeinvestor
Compiled by Globe Investor Staff





Investment
Singapore’s Temasek cuts compensation for staff responsible for FTX investment
|
May 29 (Reuters) – Singapore state investor Temasek Holdings (TEM.UL) said on Monday it had cut compensation for the team that recommended its investment in the now-bankrupt FTX cryptocurrency exchange, as well as for its senior management team.
The move comes around six months after Temasek initiated an internal review of its investment in FTX, which resulted in a writedown of $275 million.
“Although there was no misconduct by the investment team in reaching their investment recommendation, the investment team and senior management, who are ultimately responsible for investment decisions made, took collective accountability and had their compensation reduced,” Temasek Chairman Lim Boon Heng said in a statement posted on Temasek’s website on Monday.
Temasek did not detail the amount of compensation cut.
Temasek had said its cost of investment in FTX was 0.09% of its net portfolio value of S$403 billion ($304 billion) as of March 31, 2022, and that it currently had no direct exposure in cryptocurrencies.
Temasek also said last year it had conducted “extensive due diligence” on FTX, with its audited financial statement then “showed it to be profitable”.
FTX’s other backers such as SoftBank Group Corp’s (9984.T) Vision Fund and Sequoia Capital had also marked down their investment to zero after FTX, founded by Sam Bankman Fried, filed for bankruptcy protection in the U.S. last year.
“With FTX, as alleged by prosecutors and as admitted by key executives at FTX and its affiliates, there was fraudulent conduct intentionally hidden from investors, including Temasek,” Lim said in the statement on Monday. “Nevertheless, we are disappointed with the outcome of our investment, and the negative impact on our reputation.”
Temasek seeks to deliver sustainable returns over the long term by investing into early-stage companies, Lim said.
“While there are inherent risks whenever we invest, we believe that we have to invest in new sectors and emerging technologies to understand how these areas may impact the business and financial models of our existing portfolio, and whether they would be drivers of future value in an ever changing world,” Lim added.
($1 = 1.3245 Singapore dollars)





Investment
Al Gore-led fund leads $95-million investment in Toronto’s BenchSci, which uses AI to hasten drug discovery


|
Liran Belanzon, CEO of AI company BenchSci, at the company’s new Toronto offices on July 27, 2021.Fred Lum/The Globe and Mail
Al Gore’s investment firm has led a $95-million financing of a Toronto company that uses artificial intelligence to help pharma giants cut time and costs from the drug discovery process.
Generation Investment Management, chaired by the former U.S. vice-president, led the growth equity financing of BenchSci Analytics Inc., with backing from past investors Inovia Capital and Golden Ventures of Canada, and U.S.-based TCV and F-Prime Capital Partners, affiliated with Fidelity’s founding Johnson family. It’s Generation’s third deal in Canada, after 2021 investments in AlayaCare Inc. and Benevity Inc.
Terms were not disclosed but Golden managing partner Matt Golden said it was a “clean deal” free of complex structured terms that financiers have increasingly demanded from startups to guarantee them a larger share of proceeds when they sell.
Multiple investors bid to lead the deal and BenchSci chief executive Liran Belenzon said it was “not a down round,” meaning the company at least maintained its valuation from when it raised US$50-million last year. The lack of structure or devaluation puts BenchSci in rare company amid a shakeout across the tech sector as companies run out of cash or face onerous funding offers from investors.
Mr. Belenzon said “we weren’t in a position where we needed to raise money, but that’s when I want to raise. We have lots of traction and I want to make sure we have a good war chest to continue meeting demands.” He added he expects venture capital investing levels “will only get worse” despite steep declines already in the past year.
Tom Czitron: How artificial intelligence will change the investing landscape
BenchSci deploys artificial intelligence to rapidly peruse millions of scientific publications. Tens of thousands of researchers use its online subscription software tool to quickly determine which antibodies (proteins the body develops to fight invasive substances) and reagents (substances that cause chemical reactions) would be best to use in early experiments on new medications.
BenchSci’s product is used by 16 of the world’s 20 largest pharmaceutical companies, which shave months and substantial costs off the search for new drugs. Novartis in its 2021 annual report said it saved US$14-million from 2018 to 2021, as scientists using BenchSci to select the best antibodies and reagents cut down on expensive and unproductive experiments and accelerated projects by months.
Anthony Woolf, growth equity partner with Generation, a social-impact sustainability-focused investor, said his firm heard “what I’d describe as wild customer love” for BenchSci during its due diligence research. “The largest biopharmaceutical companies are spending billions of dollars a year on their preclinical research and development teams, so any degree of efficiency is meaningful to them.”
:format(jpeg)/cloudfront-us-east-1.images.arcpublishing.com/tgam/CFTTI7IOMVCBVBK5QLXCWQCMFM.jpg)
:format(jpeg)/cloudfront-us-east-1.images.arcpublishing.com/tgam/CFTTI7IOMVCBVBK5QLXCWQCMFM.jpg)
BenchSci is working towards more diversity, equity, and inclusion initiatives in the company.Fred Lum/The Globe and Mail
He added there are relatively few software tools available for early drug researchers, and that BenchSci is a welcome response to “a massive innovation crisis” in preclinical research and development that has seen the cost of drug discovery skyrocket.
BenchSci was founded in 2015 by Tom Leung, David Chen, Elvis Wianda and Mr. Belenzon after they met through the Creative Destruction Lab at University of Toronto. It has grown rapidly since the start of the pandemic, more than doubling revenue over the past 18 months and expanding its team to more than 400 people from 100 in 2020. Mr. Belenzon forecast his company would double revenue again this year but didn’t disclose absolute figures.
Asked if he was concerned generative AI companies such as OpenAI could threaten BenchSci, Mr. Belezon replied: “I think every technology can be a threat if you don’t do anything about it. We will remain agile, adopt new technologies to help us solve the problem faster and never stop as an organization.”
Mr. Woolf at Generation added: “Our conclusion is that large language models” used in generative AI “are going to benefit BenchSci over time as long as they can incorporate it.”





Investment
Singapore's Temasek cuts compensation for those responsible for FTX investment – Yahoo Canada Finance
By Urvi Manoj Dugar and Yantoultra Ngui
(Reuters) -Singapore state investor Temasek Holdings said on Monday it had cut compensation for the team and senior management that recommended its investment in the now-bankrupt FTX cryptocurrency exchange.
“Although there was no misconduct by the investment team in reaching their investment recommendation, the investment team and senior management, who are ultimately responsible for investment decisions made, took collective accountability and had their compensation reduced,” Temasek Chairman Lim Boon Heng said in a statement posted on Temasek’s website on Monday.
It did not detail the amount of compensation cut.
The move comes around six months after Temasek initiated an internal review of its investment in FTX, which resulted in a writedown of $275 million.
Temasek had said its cost of investment in FTX was 0.09% of its net portfolio value of S$403 billion ($304 billion) as of March 31, 2022, and that it currently had no direct exposure in cryptocurrencies.
Temasek also said last year it had conducted “extensive due diligence” on FTX, with its audited financial statement then “showed it to be profitable”.
FTX’s other backers such as SoftBank Group Corp’s Vision Fund and Sequoia Capital had also marked down their investment to zero after FTX, founded by Sam Bankman Fried, filed for bankruptcy protection in the United States last year.
“With FTX, as alleged by prosecutors and as admitted by key executives at FTX and its affiliates, there was fraudulent conduct intentionally hidden from investors, including Temasek,” Lim said in the statement on Monday. “Nevertheless, we are disappointed with the outcome of our investment, and the negative impact on our reputation.”
($1 = 1.3245 Singapore dollars)
(Reporting by Urvi Dugar in Bengaluru and Yantoultra Ngui in Singapore; Editing by Himani Sarkar and Lincoln Feast.)
-
Tech20 hours ago
Asmongold claims he was "kicked out" by Redfall's developers after he called the game a "boring looter-shooter with no imagination" – Sportskeeda
-
Health18 hours ago
3 tick-borne diseases, mpox added to list of notifiable diseases, illnesses in N.S. – CBC.ca
-
Art19 hours ago
Soaring value of Maud Lewis works invites fraud, art experts say – CBC.ca
-
Art19 hours ago
Couple May Need to Pay $250,000 to Have Banksy Mural Removed from Their Home – ARTnews
-
Art19 hours ago
Newmarket's Riverwalk Commons filled with art for Night Market – NewmarketToday.ca
-
Real eState19 hours ago
Downtown real estate and commercial buildings are struggling. Why won't landlords lower the rent? – Slate
-
Health14 hours ago
HIV stigma index researchers look for Manitobans with positive diagnoses to share experience
-
Economy22 hours ago
Consumer confidence is surging just as banks brace for defaults. What’s going on?